ArticleThe American journal of pathology2002
Characterization of gene expression induced by RET with MEN2A or MEN2B mutation.
Article in The American journal of pathology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 77 citations in OpenAlex.
- Fracture Risk in Pediatric Patients With MEN2B.The Journal of clinical endocrinology and metabolism · 2022Article
- Review
- Expression, function and clinical application of stanniocalcin-1 in cancer.Journal of cellular and molecular medicine · 2020Review
- Advances in understanding functional variations in the Hirschsprung disease spectrum (variant Hirschsprung disease).Pediatric surgery international · 2017Review
- Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations.Scientific reports · 2017Article
- Article
- Stanniocalcin1 (STC1) Inhibits Cell Proliferation and Invasion of Cervical Cancer Cells.PloS one · 2013Article
- Clinical significance of stanniocalcin-1 detected in peripheral blood and bone marrow of esophageal squamous cell carcinoma patients.Journal of experimental & clinical cancer research : CR · 2012Article
- RET PLCγ phosphotyrosine binding domain regulates Ca2+ signaling and neocortical neuronal migration.PloS one · 2012Article
- Lysyl oxidase: a potential target for cancer therapy.Inflammopharmacology · 2011Review
- Ret-dependent and Ret-independent mechanisms of Gfl-induced sensitization.Molecular pain · 2011Article
- How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer.Journal of thyroid research · 2011Article
- Actin depolymerizing factors cofilin1 and destrin are required for ureteric bud branching morphogenesis.PLoS genetics · 2010Article
- Etv4 and Etv5 are required downstream of GDNF and Ret for kidney branching morphogenesis.Nature genetics · 2009Article
- Regulation of microRNA expression by HMGA1 proteins.Oncogene · 2009Article
- Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice.Oncogene · 2008Article
- Simultaneous downregulation of CDK inhibitors p18(Ink4c) and p27(Kip1) is required for MEN2A-RET-mediated mitogenesis.Oncogene · 2007Article
- Evaluation of potential mechanisms underlying genotype-phenotype correlations in multiple endocrine neoplasia type 2.Oncogene · 2006Article
- RET and neuroendocrine tumors.Pituitary · 2006Review
- Searching for non-RET molecular alterations in medullary thyroid carcinoma: expression analysis by mRNA differential display.World journal of surgery · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Germ-line point mutations of the RET gene are responsible for multiple endocrine neoplasia (MEN) type 2A and 2B that develop medullary thyroid carcinoma and pheochromocytoma. We performed a differential display analysis of gene expression using NIH 3T3 cells expressing the RET-MEN2A or RET-MEN2B mutant proteins. As a consequence, we identified 10 genes induced by both mutant proteins and eight genes repressed by them. The inducible genes include cyclin D1, cathepsins B and L, and cofilin genes that are known to be involved in cell growth, tumor progression, and invasion. In contrast, the repressed genes include type I collagen, lysyl oxidase, annexin I, and tissue inhibitor of matrix metalloproteinase 3 (TIMP3) genes that have been implicated in tumor suppression. In addition, six RET-MEN2A- and five RET-MEN2B-inducible genes were identified. Among 21 genes induced by RET-MEN2A and/or RET-MEN2B, six genes including cyclin D1, cathepsin B, cofilin, ring finger protein 11 (RNF11), integrin-alpha6, and stanniocalcin 1 (STC1) genes were also induced in TGW human neuroblastoma cells in response to glial cell line-derived neurotrophic factor stimulation. Because the STC1 gene was found to be highly induced by both RET-MEN2B and glial cell line-derived neurotrophic factor stimulation, and the expression of its product was detected in medullary thyroid carcinoma with the MEN2B mutation by immunohistochemistry, this may suggest a possible role for STC1 in the development of MEN 2B phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.